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Magnesium prevents vascular 
calcification in vitro by inhibition of 
hydroxyapatite crystal formation
Anique D. ter Braake1, Paul T. Tinnemans2, Catherine M. Shanahan3, Joost G. J. Hoenderop1 & 
Jeroen H. F. de Baaij1,4
Magnesium has been shown to effectively prevent vascular calcification associated with chronic 
kidney disease. Magnesium has been hypothesized to prevent the upregulation of osteoblastic genes 
that potentially drives calcification. However, extracellular effects of magnesium on hydroxyapatite 
formation are largely neglected. This study investigated the effects of magnesium on intracellular 
changes associated with transdifferentiation and extracellular crystal formation. Bovine vascular 
smooth muscle cells were calcified using β-glycerophosphate. Transcriptional analysis, alkaline 
phosphatase activity and detection of apoptosis were used to identify transdifferentiation. Using X-ray 
diffraction and energy dispersive spectroscopy extracellular crystal composition was investigated. 
Magnesium prevented calcification in vascular smooth muscle cells. β-glycerophosphate increased 
expression of osteopontin but no other genes related to calcification. Alkaline phosphatase 
activity was stable and apoptosis was only detected after calcification independent of magnesium. 
Blocking of the magnesium channel TRPM7 using 2-APB did not abrogate the protective effects of 
magnesium. Magnesium prevented the formation of hydroxyapatite, which formed extensively 
during β-glycerophosphate treatment. Magnesium reduced calcium and phosphate fractions of 68% 
and 41% extracellular crystals, respectively, without affecting the fraction of magnesium. This study 
demonstrates that magnesium inhibits hydroxyapatite formation in the extracellular space, thereby 
preventing calcification of vascular smooth muscle cells.
Vascular calcifications are common in chronic kidney disease (CKD) and their presence is associated with 
increased cardiovascular mortality, which is the primary cause of death in CKD patients1. When glomerular 
filtration rate decreases, phosphate (Pi) levels rise and cause severely disturbed mineral and bone metabolism 
affecting vascular integrity and function2. Recently, several epidemiological studies showed a significant inverse 
relationship between serum magnesium (Mg2+) and survival in CKD patients3–5.
Mg2+ has been shown to effectively prevent mineralization in multiple experimental models of vascular cal-
cification6–13. To date, experimental research has been focused on the role Mg2+ in the medial layer of the vessel 
wall, where vascular smooth muscle cells (VSMC) actively contribute to the calcification process. VSMCs trans-
differentiate from contractile into osteoblast-like cells, which results in mineral deposition in the extracellular 
matrix, loss of contractile properties and apoptosis14. Typically, this process is characterized by the expression 
of genes normally restricted to bone tissue such as bone morphogenetic protein 2 (BMP2) and Runt-related 
transcription factor 2 (RUNX2) and increased alkaline phosphatase (ALP) activity15. Several studies suggest that 
Mg2+ directly prevents the upregulation of osteoblastic gene expression and thereby blocks VSMC transdifferen-
tiation and subsequent mineralization6–8,11,16,17. However, extracellular inhibition of Mg2+ on calcium (Ca2+)-Pi 
particle formation, which is an important driving force for the onset of calcification, has largely been neglected18. 
Interestingly, it has been suggested that Ca2+-Pi nanocrystals, rather than Pi, may drive osteoblastic transdifferen-
tation of VSMC19, illustrating the relevance of crystal inhibiting effects of Mg2+. Though poorly studied in detail 
in the context of VSMC calcification, the extracellular crystal inhibitory properties of Mg2+ are profound and well 
known in both biological and non-biological systems20–22.
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This study aimed to investigate the effects of Mg2+ on both intracellular changes associated with vascular calci-
fication  and crystal formation in the extracellular space. Therefore, in addition to mapping the effects of Mg2+ on 
gene expression patterns associated with osteoblastic transdifferentiation in VSMC, we studied the effects of Mg2+ 
on the formation of crystals in the extracellular space by scanning electron microscopy and X-ray diffraction.
Materials and Methods
Cell culture and vascular smooth muscle cell identification. Bovine aortic VSMC (bVSMC) were 
set up from explant culture of bovine aortic segments according to standard protocols and cultured in M199 
culture medium (Lonza, Basel, Switzerland) supplemented with 10% (v/v) fetal bovine serum (FBS, HyClone, 
GE Healthcare Life Sciences, Illinois, USA), ciprofloxacine (Fresenius Kabi, Zeist, The Netherlands) at 37 °C 
in a humidified incubator with 5% (v/v) CO2. Standard culture medium contained 0.8 mM MgSO4, 1.02 mM 
NaH2PO4 and 1.8 mM CaCl2. VSMC were not used beyond the 16th passage and VSMC identity was confirmed 
by α-smooth muscle actin (α-SMA) immunofluorescent stainings. α-SMA staining was performed on cells that 
were cultured on coverslips (18 mm in diameter) until 80% confluent. After fixation in 4% (w/v) paraformal-
dehyde and blocking with 16% (v/v) normal goat serum, the cells were stained overnight (4 °C) with a mouse 
monoclonal primary anti-α-SMA antibody diluted (1:400, A5228, Sigma, Missouri, USA) in a buffer containing 
phosphate buffered saline (PBS) and normal goat serum. Subsequently, cells were stained with a goat-anti mouse 
IgG Alexa 488 conjugated polyclonal antibody (1:250, A-11029, Invitrogen, Massachusetts, USA) and visualized 
using an Axio Imager M (Zeiss, Oberkochen, Germany).
Experimental design. For calcification, medium was supplemented with 5% (v/v) FBS and 10 mM 
β-glycerophosphate (BGP, Merck Millipore, Massachusetts, USA). BGP requires cellular activity for its cleavage 
to free Pi, and was chosen in this setup to increase the medium Pi concentration to minimize Mg2+-Pi interac-
tions prior to cellular exposure. In the high Mg2+ treatment medium, MgCl2 (Merck Millipore) was supplemented 
to reach a final concentration of 2 mM MgCl2. At 80% confluence, cells grown in a 12-wells plate were incubated 
with designated media for 14 days, which was changed every 2–3 days.
TRPM7 inhibition by 2-APB. Transient receptor potential melastatin 7 (TRPM7) was inhibited by incu-
bation with 10 μM of 2-Aminoethyl diphenylborinate (2-APB, Sigma). At 80% confluence, 2-APB was supple-
mented in combination with the different culture media as outlined in the previous section during 14 days in a 
24-wells plate.
Pi concentration of the cell culture supernatant. Pi was measured in the cell culture supernatant (or 
culture medium) calorimetrically using the malachite green method as described elsewhere23. Briefly, a reaction 
mix consisting of molybdate and malachite green was added to the samples and standards and incubated for 
30 minutes at room temperature. The absorbance was measured at 620 nm using a Benchmark Plus Microplate 
Spectrophotometer System (Bio-Rad, California, USA).
Quantification of Ca2+ deposition. Cells were decalcified with 0.1 M HCl for 5 minutes at room tem-
perature with gentle rocking, which effectively dissolved all Ca2+ deposits present. The Ca2+ concentration in 
the supernatant was determined by the o-cresophthalein complexone method. o-cresophthalein color reagent 
(Sigma) was incubated with the samples and standards and the absorbance was measured immediately at 570 nm, 
as described previously24. Subsequently, the cells were neutralized in PBS and lysed in 0.1 M NaOH/0.1% (w/v) 
sodium dodecyl sulfate for total protein isolation. Ca2+ concentrations were normalized for total protein as 
determined by Pierce BCA protein detection kit according to the manufacturer’s instructions (Fisher Scientific, 
Massachussets, USA).
Alizarin Red staining. Calcification was visualized by the Alizarin Red S staining method for Ca2+. Cultures 
were washed with PBS, fixed in 4% (v/v) formalin for 15 minutes and washed with demineralized H2O before 
staining with 2% (w/v) aqueous Alizarin Red (Sigma) for 5 minutes.
RNA isolation and real-time polymerase chain reaction (RT-qPCR). Total RNA was extracted from 
VSMC using TRIzol (Invitrogen) and treated with DNAse (1 U/μg RNA, Promega, Wisconsin, USA) to remove 
genomic DNA. cDNA was synthesized from 1.5 μg total RNA by Moloney Murine Leukemia Virus reverse tran-
scriptase (Invitrogen) for one hour at 37 °C. The primers used for PCR amplification are shown in Table 1 and 
were equally efficient. RT-qPCR was executed in duplicate using IQ SYBRGreen Mix according to the manufac-
turers protocol (Bio-Rad), using a Bio-Rad thermos-cycler (Bio-Rad). The expression of target genes was normal-
ized to GAPDH expression levels.
Alkaline phosphatase activity assay. Cells grown in 12-well plates and cultured in designated media for 
2, 8 and 14 days were lysed with 1% (v/v) Triton X-100 in PBS containing protease inhibitors. ALP activity was 
determined in the total lysate as the hydrolysis of p-nitrophenyl phosphate (sigma) into p-nitrophenol in a basic 
buffer by ALP by p-nitrophenol production. The reaction was incubated for 30 minutes at 37 °C and the absorb-
ance for p-nitrophenol was measured at calorimetrically at 410 nm for both p-nitrophenol (Sigma) standards 
and samples. One unit (U) was defined as the production of 1 µmol p-nitrophenol per minute per gram protein.
Detection of apoptosis. Occurrence of apoptosis was measured using the Annexin V-FITC Apoptosis 
Detection Kit (ab14085 Abcam, Cambridge, UK). Due to the presence of calcifications, the method for adherent 
cells was used according to the manufacturer’s instructions. Briefly, cells were incubated with Annexin-V-FITC 
and propidium iodide in binding buffer for 5 minutes at room temperature. Apoptotic cells were detected by 
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immunofluorescence microscopy using a FITC and Texas Red filter on an Axio Imager M (Zeiss). Apoptosis was 
quantified using ImageJ software (NIH, Maryland, USA) by calculating the ratio of the area positive for FITC 
signal versus total area, as the mean of multiple captures in 3 replicates per treatment per time-point.
Crystal isolation for X-ray diffraction, scanning electron microscopy and energy-dispersive 
spectroscopy analysis. Cell culture supernatants of BGP-treated cells in 6-well plates with and without 
2 mM MgCl2 were collected and purified. Supernatants were centrifuged for one hour at 16 000 × g19. The pellets 
containing the nanocrystals were washed with demineralized H2O and then re-centrifuged. Subsequently, the 
crystal pellets were dried and used for analysis. One measurement represents the crystals formed in a total of 7 
wells containing 2 ml of culture medium in the BGP treated cultures. As less material was formed in the BGP cul-
tures supplemented with Mg2+, one measurement represents the crystals formed in a total of 21 wells containing 
2 ml of culture medium in order to reach sufficient amounts to detect by X-ray diffraction. For X-ray diffraction 
analysis, diffractograms were measured on a PANalytical Empyrean (PANalytical, Almelo, the Netherlands) in 
transmission mode with fine-focus sealed tube, focusing mirror and PIXcel3D detector, using CuKα radiation. 
The samples were measured in a capillary, using 0.5 mm soda glass capillaries with a wall thickness of 0.01 mm. 
For scanning electron microscopy (SEM) (GeminiSEM, Zeiss) in combination with energy-dispersive spectros-
copy (EDX) for elemental analysis (QUANTAX 200, Bruker) the crystal pellets were transferred onto copper 
tape and coated with carbon. High-resolution pictures were obtained using an Everhart-Thornley SE detector. 
Accelerating voltage was 5 kV for morphological observations and 15 kV for micro-elemental analyses. Due to 
the use of BGP as calcification inducer, a cell-free control could not be included as cellular presence is necessary 
to cause Pi accumulation in the medium (data not shown).
Statistics. Parametric data were analyzed by One-Way ANOVA with Tukey’s post-hoc test to correct for 
multiple comparisons using PRISM software (GraphPad, San Diego, CA). Non-parametric data as identified by 
Shapiro-Wilk test for normality were analyzed using Kruskall-Wallis analysis with Dunn’s correction for multiple 
analysis. Time-course data was analyzed using a Two-Way ANOVA. All data are shown as mean ± SEM. P < 0.05 
was considered statistically significant.
Results
β-glycerophosphate supplementation resulted in increased medium Pi concentration. BGP 
is a Pi-donor that requires enzymatic cleavage in order to release Pi. As Pi exposure is one of the decisive factors 
in the calcification process, the Pi concentration of the cell culture supernatant was assessed after 2, 8 and 14 
days of treatment (Fig. 1). 10 mM BGP treatment resulted in gradual increase in Pi concentration over time, 
reaching 4.6 ± 0.3 mM after 14 days. 2 mM Mg2+ supplementation led to significantly higher Pi concentrations of 
7.6 ± 0.8 mM after 14 days. In contrast, BGP treatment in cell-free conditions did not lead to increased Pi concen-
trations under the same conditions (data not shown).
Mg2+ prevents vascular smooth muscle cell  mineralization. The effect of BGP on the development 
of calcifications was studied using cellular Ca2+ measurements and visualized by Alizarin Red staining (Fig. 2). 
10 mM BGP treatment of bVSMC resulted in variable but pronounced calcification after 14 days (146 ± 93 versus 
2.5 ± 0.2 µg Ca2+ per gram protein in the control condition, p < 0.05). Ca2+ deposition was completely prevented 
by 2 mM Mg2+ in our model (3.5 ± 0.3 µg/g protein Ca2+).
β-glycerophosphate supplementation upregulated OPN gene expression but did not result in 
changes in mRNA expression of calcification activators. To assess the effects of Mg2+ involved in the 
prevention of VSMC calcification, gene expression levels of ACTA2 and osteogenic transcription factors RUNX2 
and BMP2 were assessed after 2, 8 and 14 days (Fig. 3a–c). 10 mM BGP treatment did not result in expression 
changes of ACTA2, RUNX2 and BMP2 over the time course of calcification. 2 mM Mg2+ supplementation did not 
affect these expression levels. Both ACTA2 and BMP2 mRNA expression significantly increased over time in all 
conditions, independent of BGP treatment (Fig. 3a–c). In addition, mRNA expression levels of calcification inhib-
itors OPG, OPN and MGP were assessed (Fig. 3d–f). OPG expression was significantly downregulated by Mg2+ 
supplementation compared all other treatments after 8 days. No effect of BGP was observed at all time-points. 
MGP gene expression showed a significant increase over time in all treatment groups, while no effect of BGP was 
Gene (Bos Tauros) Forward primer sequence Reverse primer sequence
GAPDH 5′-AAGATTGTCAGCAATGCCTCC-3′ 5′-TGGACAGTGGTCATAAGTCCC-3′
ACTA2 5′-TCTTTGAAGGCAAAGACCTGG-3′ 5′-ATTCCCTCTTATGCTCCTGGG-3′
RUNX2 5′-AGGCGCATTTCAGATGATGAC-3′ 5′-ACCTGCCTGGCTCTTCTTAC-3′
BMP2 5′-GCAGCTTCCATCACGAAGAATC-3′ 5′-CCGAAAGACCTGAAGTTCTGC-3′
ALPL 5′-ACCTCCGTAGAAGACACACTG-3′ 5′-GCCAGACCAAAGATCGAGTTG-3′
TRPM7 5′-GTCGTATGTGAAGGAACAGGC-3′ 5′-TGCATCAGGAAGATTCCCTCC-3′
MGP 5′-TGGCAGCTCTGTGTTATGAATC-3′ 5′-GGCTTTTGCTCTCCATCTCTG-3′
OPN 5′-CTAACGTTCAGAGTCCAGATGC-3′ 5′-TTGGAAAGCTCGCTACTGTTG-3′
OPG 5′-AAAGCGCCCTGTAGAAAACAC-3′ 5′-ACAGGGTCATGTCTATTCCGC-3′
Table 1. Bovine qPCR primer sequences.
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observed. After 14 days, BGP significantly increased OPN expression, which was prevented by Mg2+. In addition 
to osteogenic transcription factors, ALP is a well-known indicator for osteoblastic maturation. Therefore, ALP 
mRNA expression and activity were measured to assess the effect of Mg2+ on the development of an osteoblastic 
phenotype after 2, 8 and 14 days. BGP did not change ALPL mRNA expression and ALP activity, which remained 
stable after Mg2+ supplementation (Fig. 3g,h).
VSMC mineralization preceded apoptosis. As apoptosis accelerates VSMC calcification in vitro25, 
the occurrence of apoptosis was assessed in VSMC at 2, 8 and 14 days (Fig. 4). 10 mM BGP treatment did 
not result in increased apoptosis before the onset of calcification at 2 and 8 days. After 14 days, apoptosis was 
observed in calcified regions. Mg2+ prevented calcification at all time-points as apoptosis was not detected in the 
Mg2+-supplemented BGP cells.
TRPM7 was not involved in the protective effect of Mg2+ against β-glycerophosphate-induced 
calcification. TRPM7 is the main Mg2+ channel in VSMCs26. To examine whether a TRPM7-mediated 
increasing intracellular Mg2+ concentration prevents VSMC calcification, VSMCs were treated with 10 µM 
2-APB, which is a TRPM7 blocker11. 2-APB treatment of Mg2+ supplemented BGP cultures did not reverse the 
protective effect of Mg2+ on BGP-induced VSMC calcification (Fig. 5a). Furthermore, 10 mM BGP treatment did 
not affect TRPM7 mRNA expression levels in cultured VSMC (Fig. 5b).
Figure 1. BGP increased medium Pi concentration. bVSMC were cultured with 10 mM BGP and the Pi 
concentration in the cell culture supernatant was measured in whole media at 2 (white bars), 8 (striped 
bars) and 14 (black bars) days. Data are shown as the mean of 3 individual experiments (each consisting of 
3 replicates) ±SEM. Unless shown otherwise, *Indicates P < 0.05 versus control. BGP, β-glycerophosphate; 
bVSMC, bovine vascular smooth muscle cells; Pi, inorganic phosphate; SEM, standard error of the mean.
Figure 2. High Mg2+ prevented mineralization, despite high medium Pi concentrations. Quantification of 
calcification by cellular calcium deposition at 2 (white bars), 8 (striped bars) and 14 (black bars) days during 
calcification by BGP supplementation (a) and Alizarin Red staining for calcium (b). Calcium deposition data 
are shown as the mean of 3 individual experiments (each consisting of 3 replicates) ±SEM. *Indicates P < 0.05 
versus control. Scale bar corresponds with 100 µm. BGP, β-glycerophosphate; Pi, inorganic phosphate; SEM, 
standard error of the mean.
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Figure 3. Bovine VSMC did not underdo osteogenic transdifferentiation after BGP treatment. mRNA 
expression of ACTA2 (a), osteogenic transcription factors RUNX2 (b) and BMP2 (c) and calcification inhibitors 
OPG (d), OPN (e) and MGP (f) were measured after 2 (white bars), 8 (striped bars) and 14 (black bars) days of 
BGP supplementation in presence or absence of Mg2+. mRNA levels were normalized for GAPDH expression 
and are shown relative to the 2-day control. ALP activity (g) and mRNA expression (h) remained stable during 
BGP treatment. Data are shown as the mean of 3 individual experiments (each consisting of 3 replicates) ±SEM. 
Unless shown otherwise, significance is indicated versus control (*Indicates P < 0.05). ACTA2, α-smooth 
muscle actin; ALPL, alkaline phosphatase; BGP, β-glycerophosphate; BMP2, bone morphogenetic protein 2; 
bVSMC, bovine vascular smooth muscle cells; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; MGP, 
matrix gla protein; OPG, osteoprotegerin; OPN, osteopontin; RUNX2, Runt-related transcription factor 2; SEM, 
standard error of the mean.
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Mg2+ prevented β-glycerophosphate-induced formation of extracellular hydroxyapatite crystals. 
To investigate the potential role of Mg2+ in crystal growth and formation, the cell culture supernatants of 
BGP-treated cells in the presence or absence of Mg2+ were analyzed for the incidence of crystals using X-ray pow-
der diffraction. In the BGP-treated samples, the X-ray diffraction patterns revealed the presence of a considerable 
amount of hydroxyapatite crystals (Fig. 6). The broadening of the hydroxyapatite diffraction peaks, compared to 
the NaCl peaks, indicate that the hydroxyapatite crystals are nano-sized. Both crystals isolated from the cell cul-
ture supernatants and a synthetic hydroxyapatite standard, that was used as positive control, matched with a refer-
ence diffraction pattern specific for hydroxyapatite crystals (see Supplemental Fig. 2). Hydroxyapatite diffraction 
peaks were absent in the Mg2+-supplemented BGP supernatants. Of note, no crystals other than hydroxyapatite 
and NaCl were identified. As X-ray diffraction exclusively detects crystalline material and not amorphous mate-
rial, isolated particles were analyzed by SEM-EDX for morphology and elemental composition (Fig. 7). EDX 
analysis revealed a reduced Ca2+ and Pi fraction in crystal clusters of 68% and 41% after Mg2+ supplementation, 
respectively, without increasing the fraction of Mg2+ present in the crystal clusters (Fig. 7b,c).
Discussion
Here, we demonstrate that Mg2+ inhibits bVSMC mineralization through inhibition of Ca-apatite formation in 
the extracellular space, independent of VSMC transdifferentiation. Our most important finding is the absence of 
Figure 4. Calcification preceded bVSMC apoptosis. Apoptosis was detected on adherent cells by Annexin-V 
FITC conjugated antibody quantified at 2 (white bars), 8 (striped bars) and 14 (black bars) days of BGP 
supplementation in presence or absence of Mg2+ (a). Nuclei are stained with DAPI (blue), Annexin-V positive 
cells (green) indicate apoptosis (arrows), which was observed only after onset of calcification at 14 days. 
Images represent 3 individual experiments. Scale bars correspond to 200 µm (upper panel) and 100 µm (lower 
panel). Prior to calcification, as represented by 2-day and 8-day treated samples, no apoptosis was detected (b). 
*Indicates P < 0.05 versus control. BGP, β-glycerophosphate.
Figure 5. Inhibition of TRPM7 did not abrogate the protective effects of Mg2+. Ca2+ deposition was measured 
in calcifying bVSMC supplemented with Mg2+ cultured with 10 µM 2-APB, a TRPM7 inhibitor, for 14 days 
(a). In calcifying bVSMC, mRNA expression levels of TRPM7 were not affected after 2 (white bars), 8 (striped 
bars) and 14 days (black bars) (b). Data are shown as the mean of 3 individual experiments (each consisting 
of 3–4 replicates) ± SEM. *Indicates P < 0.05 versus control. 2-APB, 2-Aminoethyl diphenylborinate; BGP, 
β-glycerophosphate; bVSMC, bovine vascular smooth muscle cells; TRPM7, transient receptor potential 
melastatin.
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hydroxyapatite crystals in the medium of BGP-treated bVSMCs supplemented with Mg2+. Characterization by 
SEM-EDX confirmed the reduction of Ca-apatite crystals in Mg2+-supplemented supernatants, without incor-
poration of Mg2+ in the formed crystals. Underlining the strong capacity of Mg2+ to block crystal formation, 
2 mM Mg2+ was sufficient to prevent the calcification process, even though extracellular Pi levels rise to 7 mM 
in Mg2+-BGP treated bVSMCs. Moreover, intracellular action of Mg2+ is not likely in our setup, because when 
cellular Mg2+ uptake was impaired using TRPM7-blocker 2-APB, Mg2+ still prevented vascular calcification11. 
Accordingly, we propose that Mg2+ prevents VSMC mineralization through the inhibition of hydroxyapatite for-
mation in the extracellular space, blocking its deposition on VSMC.
Hydroxyapatite (Ca10(PO4)6(OH)2) is the most abundant type of crystal in uremic arterial calcifications and its 
formation has been shown to be essential for VSMC transdifferentiation and vascular calcification19,27. Although 
it has been suggested that the potential incorporation of Mg2+ in Ca-apatite crystals (whitlockite, Ca9Mg(HPO4)
(PO4)6), may reduce crystal pathogenicity and increase solubility, we did not identify any whitlockite after Mg2+ 
treatment. Our data suggest that Mg2+ most likely prevents crystal nucleation, rather than affecting crystal con-
tent. These findings are in line with previous studies that exclusively identified hydroxyapatite, and not whitlock-
ite, in deposits on calcifying VSMC supplemented with Mg2+ 28. Indeed, high concentrations of Mg2+ led to less 
hydroxyapatite deposition in a study by Louvet et al.29. Given the lack of crystals after Mg2+ supplementation, our 
results indicate that Mg2+ inhibits the early phases of crystal assembly in high Pi-media. Moreover, we hypothe-
size that the incorporation of Pi in hydroxyapatite in the BGP condition explains the lower free Pi concentration 
in BGP-treated compared to the Mg2+-BGP-treated culture media.
Initial Ca-Pi particle formation in response to elevated Pi-levels has shown to occur in a cell-independent 
manner, subsequently initiating VSMC transdifferentiation when native VSMC inhibitory capacities dimin-
ish19,30. Though poorly studied in the context of VSMC mineralization, Mg2+ is known to stabilize amorphous 
Ca-Pi particles and therefore inhibit Ca-apatite maturation in acellular systems31–36. While the exact mechanisms 
remain unknown, evidence suggests that Mg2+ may stabilize extracellular ATP. Hydrolysis of ATP is necessary 
for hydroxyapatite nucleation21. The importance of crystal maturation in the initiation of VSMC transdifferenti-
ation and vascular calcification has been frequently emphasized18,19,30,37. Recently, Ca-Pi-containing soluble nan-
oparticles or calciprotein particles (CPP) were shown to stimulate calcification37. Interestingly, Mg2+ delays CPP 
maturation in uremic serum38. These findings support that Mg2+ prevents mineralization by directly inhibiting 
Ca-apatite crystal formation or maturation in the extracellular space.
Mg2+ supplementation has repeatedly shown to prevent osteogenic gene expression. As a result, osteogenic 
gene expression has been repeatedly considered as Mg2+ target to prevent osteoblastic transdifferentiation39. In 
line with this hypothesis, previous research showed that Mg2+ concentrations as low as 0.8 mM reversed estab-
lished calcification in human VSMC, which could be abrogated by 2-APB treatment17. These results suggest that 
cellular Mg2+ uptake via TRPM7 prevents VSMC calcification7,11,17. However the role of TRPM7 is controversial, 
as recent evidence suggests that interleukin-18 enhanced VSMC calcification through TRPM7 activation40. In our 
model, TRPM7 inhibition by 2-APB did not affect the Mg2+ rescue.
bVSMC are characterized by high basal expression levels of ALP, which makes them prone to calcification. 
Despite their susceptibility to calcify, the bVSMCs are contractile and do not present any signs of osteoblastic trans-
differentiation, as high levels of ACTA2 expression and α-SMA protein expression were preserved in response 
to BGP supplementation. Although our bVSMCs strongly calcified, BGP treatment did not result in osteogenic 
conversion as demonstrated by stable expression of BMP2, RUNX2 and ALPL among treatments14. Interestingly, 
both mRNA expression of BMP2 and ACTA2 increased over time. However, these observations were irrespective 
Figure 6. Impact of Mg2+ on BGP-induced Ca2+-apatite formation. X-ray powder diffraction analysis of cell 
culture supernatants show presence of NaCl (*) and Ca-apatite (arrows) in BGP treated cultures (black line), 
but not in BGP cultures supplemented with Mg2+ (gray line). Of note: as the BGP culture supplemented with 
Mg2+ contained less precipitates; one measurement represents 21 cultures (6-well format) compared to 7 in the 
BGP condition in order to reach the detection threshold. BGP, β-glycerophosphate.
www.nature.com/scientificreports/
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of treatment and are therefore not related to osteoblastic transdifferentiation of the bVSMC. The only transcrip-
tional response observed during BGP-induced calcification was upregulation of the OPN gene after 14 days, which 
was prevented by Mg2+. Increased OPN expression is associated with calcification19,41,42. OPN is an inhibitor of 
calcification and potently inhibits hydroxyapatite growth and OPN upregulation has been shown to reflect a protec-
tive mechanism in response to the phosphate- and hydroxyapatite-rich environment by VSMC43–45. The absence of 
OPN upregulation in Mg2+-supplemented BGP cultures may therefore be explained by the lack of Ca-Pi formation. 
Figure 7. Crystal or particle clusters formed in BGP cell culture supernatant are morphologically and 
chemically distinct. Morphology of crystal clusters formed in BGP and in BGP supplemented with Mg2+ 
cell culture supernatants, as overview (upper) and focused (lower) for EDX analysis (a). The averaged 
EDX-spectrum and resulting quantification of the crystal cluster isolated from Mg2+ supplemented culture 
supernatant reveals reduced Ca (green) and P (purple), as visualized in the elemental map (c) compared to 
crystal clusters found in BGP treated cultures (b). In addition, Mg2+ supplemented crystal clusters showed 
increased Na (blue) and Cl (orange) compared to BGP crystal clusters. Data are presented as mean of the 
analyses of ten individual crystal clusters. BGP, β-glycerophosphate; CPS, counts per second; EDX, energy 
dispersive spectroscopy; (k)eV, (kilo)-electron volt.
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Moreover, OPN is only increased at 14 days after calcification was already manifested, suggesting it to be resulting 
from calcification rather than causing. In addition to osteoinductive signaling, apoptosis has been shown to induce 
the progression of calcification25. Our results indicate that calcification precedes apoptosis, as apoptosis was only 
detected after 14 days of BGP treatment when calcification was already manifested. In our setup, apoptosis is likely 
the result of exposure to Ca-Pi crystals, rather than a causative factor for calcification46.
In human, rodent and bovine calcification models evidence strongly suggests that calcification is a result of 
VSMC undergoing osteogenic transdifferentiation and that Mg2+ effectively abrogates this through upregulation 
of calcification inhibitors and downregulation of osteogenic genes6–8,11,16,17,47,48. Indeed, we show the effective 
inhibition of Mg2+ in VSMC calcification. However, in contrast to previous studies, our results suggest that cal-
cification is driven by extracellular hydroxyapatite formation independent of osteogenic transdifferentiation in 
bVSMCs. While many studies show the association between osteogenic transdifferentiation and vascular calci-
fication, it remains debatable whether this transdifferentiation is an undisputable prerequisite for the develop-
ment of mineralization49. Calcification represents the final common pathway of multiple pathological vascular 
processes50. Our results do not contradict intracellular Mg2+ effects on osteoblastic transdifferentation. However, 
they do highlight the presence of alternative extracellular effects on crystal formation. Overall, it is important 
to note that potential intracellular and extracellular pathways involved in the calcification-inhibiting capacity 
of Mg2+ are not mutually exclusive. Given the strong effect of Mg2+ on calcification independent of osteogenic 
pathways, however, the relative contribution of crystal inhibition compared to any intracellular targets may be 
considerable and underestimated to date.
An important strength of this study is that our model favored to study the effects of Mg2+ on extracellular 
crystal growth, independent of genetic VSMC transdifferentiation. Although it has been reported previously that 
Mg2+ inhibits calcification, most study set-ups do not allow to discriminate between extracellular reduction of 
crystal formation and intracellular inhibition of osteogenic conversion6–8,11,17. A limitation of this study is that 
while we show that TRMP7 seems not to be involved in calcification, we cannot exclude that other Mg2+ channels 
than TRPM7 facilitate Mg2+ entry into the bVSMCs. However, it was shown previously that TRPM7 is the main 
Mg2+ channel in VSMCs26. Therefore, the contribution of other transporters is likely minor. In addition, we show 
the effectiveness of Mg2+ primarily through extracellular mechanisms involving hydroxyapatite. In contrast to 
other studies, the driving force of calcification in our model is not osteoblastic transdifferentiation but mainly 
hydroxyapatite formation and deposition. Therefore, any intracellular effects of Mg2+ involving modification of 
osteogenic genes such as BMP2 and RUNX2 cannot be excluded.
In conclusion, our findings demonstrate a role for Mg2+ in preventing VSMC mineralization involving direct 
extracellular Ca-apatite crystal inhibition. An increasing body of studies now report that Mg2+ prevents vascular 
calcification by extracellular Pi binding. Mg2+ has been shown to reduce both vascular and non-vascular calcifi-
cations and to improve calcification propensity, favoring a non-cellular mechanism of action38,51. Therefore, Mg2+ 
may be considered an important and realistic approach to potentially reduce the risk for vascular calcification 
and subsequent cardiovascular complications in CKD patients. Clinical trials are warranted to further assess the 
clinical relevance of Mg2+ in relation to vascular calcifications.
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